Clinical Trials


Phase 2B trial in Secondary Progressive Multiple Sclerosis

A Phase 2B randomized, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in the treatment of subjects with Secondary Progressive Multiple Sclerosis (SPMS) is currently recruiting up to 90 patients in Australia and New Zealand. Recruitment will close March 31, 2016. Patients with SPMS who might be interested in taking part in the trial should contact the study coordinator at one of the following sites as soon as possible:


Western Australian Neuroscience Institute (WARNI), QEII Medical Centre, Verdun Street, Nedlands, Western Australia 6009. Please contact Sue Walters, phone (08) 9346 4884 or email

Neurodegenerative Disorders Research (NDR), 4 Lawrence Avenue, West Perth, Western Australia 6005. Please contact Cheryl MacFarlane, phone (08) 9481 6293 or email   


Nucleus Network, 5th Floor, Burnet Tower, 89 Commercial Road, Melbourne, Victoria, Australia, 3004. Please contact Mary Franich, phone (03) 9076 8900 or email


The Wesley-St. Andrew’s Research Institute (WSARI), The Wesley Hospital, 451 Coronation Drive, Auchenflower, Queensland 4066. Please contact Helen Woodhouse, phone (07)  3721 1523 or email


PARC Clinical Research, Royal Adelaide Hospital, North Terrace Adelaide 5000. Please contact Kathy Heyman, phone (08) 8222 2712 or email


P3 Research, 1st Floor, 121 Adelaide Road, Wellington, New Zealand 6021. Please contact Mary McKay, phone (04) 801 0002 ext 758 or email


Optimal Clinical Trials, 85 Grafton Road, Grafton, Auckland, New Zealand 1010. Please contact Liz Smaill, phone (09) 303 4987 or email


Further details about the study, including patient eligibility criteria, can be viewed at:

>>> National Multiple Sclerosis Society (US) - letter of support for Phase 2B trial

>>> MS Research Australia - letter of support for Phase 2B trial